ADAMTS4 is a serum biomarker for pulmonary arterial hypertension associated with congenital heart disease.
Serum ADAMTS4 helps identify congenital heart disease patients who have pulmonary arterial hypertension.
ADAMTS4 is a serum biomarker for pulmonary arterial hypertension associated with congenital heart disease.
Pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD) is a cardiopulmonary disorder characterized by pathological pulmonary vascular remodeling and perivascular inflammatory cell infiltration.
This study aimed to evaluate the diagnostic performance and prognostic value of serum ADAMTS4 in patients with PAH-CHD.
This study included patients with PAH-CHD, patients with CHD, and healthy controls.
higher ADAMTS4 reliably distinguishes PAH from CHD alone
Compared with those in CHD patients and healthy controls, serum ADAMTS4 levels were elevated in PAH-CHD patients.
ADAMTS4 was positively correlated with NT-proBNP ( r = 0.45, p = 0.002), CRP ( r = 0.60, p < 0.001), and WHO functional class ( r = 0.49, p < 0.001).
After multivariable adjustment, logistic regression revealed that ADAMTS4 remained an independent factor associated with the presence of PAH-CHD (OR = 1.189; 95% CI: 1.036-1.365; p = 0.014).
Kaplan-Meier analysis revealed significantly shorter event-free survival in patients with ≥ 42.2 ng/mL ADAMTS4 than in those with lower levels (log-rank p = 0.046).
Serum ADAMTS4 is elevated in patients with PAH-CHD and is correlated with disease severity and adverse outcomes.
These findings support its utility as a noninvasive serum biomarker for diagnosis, risk stratification and prognostic assessment in PAH-CHD patients.